Form 4: AEON Biopharma Chief Medical Officer Granted Over 1.3 Million Restricted Stock Units

AEON Biopharma's Chief Medical Officer, Chad Oh, was granted 1,316,872 Restricted Stock Units (RSUs) on May 21, 2025, as part of his compensation.

Summary

• Chad Oh, the Chief Medical Officer of AEON Biopharma, Inc. (AEON), was granted 1,316,872 Restricted Stock Units (RSUs).
• The transaction date for this grant was May 21, 2025.
• Each RSU will be settled in cash based on the fair market value of AEON's Class A Common Stock on the applicable vesting date.
• The RSUs will vest over a four-year period, with 25% vesting on each anniversary of May 21, 2025.
• Following this transaction, Chad Oh beneficially owns 1,316,872 Restricted Stock Units directly.
• The filing was made on May 23, 2025, and indicates the transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of RSUs to a key executive is generally a positive sign, indicating management retention and alignment with shareholder interests, though it doesn't directly impact current financial performance.

Positives

• The grant of Restricted Stock Units (RSUs) aligns the Chief Medical Officer's interests with long-term shareholder value, as the value of the compensation is tied to the company's stock performance.
• This equity grant serves as a significant retention incentive for a key executive, promoting stability in leadership.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent compensation structure.

Negatives

• The RSUs do not provide immediate cash value to the recipient; their value is realized only upon vesting and is dependent on the future fair market value of the company's stock.
• The vesting schedule means the full benefit of the grant is deferred over four years.

Risks

• The ultimate value of the Restricted Stock Units to the recipient is subject to the future performance and market price of AEON Biopharma's Class A Common Stock.
• Should the company's stock price decline significantly, the value of the RSUs upon vesting could be lower than anticipated.

Future Outlook

The grant of long-term equity incentives to a key executive like the Chief Medical Officer suggests a strategic focus on retaining talent and aligning management's long-term interests with the company's future performance and shareholder value creation.

Management Comments

• The grant of 1,316,872 Restricted Stock Units to Chief Medical Officer Chad Oh is a standard component of executive compensation, designed to incentivize long-term performance and retention.

Industry Context

Equity-based compensation, particularly through Restricted Stock Units (RSUs), is a common and widely accepted practice in the biotechnology and pharmaceutical industries for attracting, retaining, and motivating key executives. This aligns executive incentives with the long-term success and stock performance of the company, which is crucial in a sector with long development cycles and significant R&D investments.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice across the biotechnology and pharmaceutical industries, similar to compensation structures seen at companies like Amgen, Gilead Sciences, or Moderna.
• The vesting schedule of 25% annually over four years is a typical industry standard for long-term incentive plans, designed to ensure executive retention and sustained performance over several years.
• While specific comparable grant sizes would depend on the company's market capitalization, executive role, and overall compensation philosophy, the mechanism of granting RSUs at a $0 price, with cash settlement based on fair market value, is consistent with common practices for equity compensation in the sector.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Chad Oh, the Chief Medical Officer, constitutes a related party transaction as it involves compensation to a key executive of the company.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Medical Officer's financial incentives with the company's stock performance, potentially leading to better long-term value creation.
• Employees (Executives): Chad Oh receives a significant equity grant, which serves as a key component of his compensation and a strong incentive for retention and performance.

Next Steps

• The Restricted Stock Units will begin vesting on May 21, 2026, with subsequent vesting occurring annually on May 21st for the following three years.

Key Dates

Keywords

AEON Biopharma, AEON, Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Chad Oh, Chief Medical Officer, Equity Grant, 10b5-1 Plan